BIOMARIN PHARMACEUTICAL INC Inventory, Finished Goods, Net of Reserves
BIOMARIN PHARMACEUTICAL INC (BMRN) had Inventory, Finished Goods, Net of Reserves of $283.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-06
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $283.08M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $120.76M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $391.31M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $485.70M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $283.08M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $120.76M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $391.31M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $485.70M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $480.89M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $469.36M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $527.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $535.79M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $423.70M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $390.38M 10-Q · filed 2024-04-26 |
| 2023-12-31 | $380.37M 10-K · filed 2025-02-24 |
| 2023-09-30 | $371.13M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $358.70M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $342.88M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $352.36M 10-K · filed 2024-02-26 |
| 2022-09-30 | $304.48M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $268.34M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $291.93M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $281.14M 10-K · filed 2023-02-27 |
| 2021-09-30 | $261.64M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $253.30M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $279.60M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $313.59M 10-K · filed 2022-02-25 |
| 2020-09-30 | $330.31M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $292.57M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $251.48M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $255.85M 10-K · filed 2021-02-26 |
| 2019-09-30 | $219.59M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $208.11M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $191.47M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $225.19M 10-K · filed 2020-02-27 |
| 2018-09-30 | $210.90M 10-Q · filed 2018-10-26 |
| 2018-06-30 | $192.45M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $220.94M 10-Q · filed 2018-04-27 |
| 2017-12-31 | $191.22M 10-K · filed 2019-02-28 |
| 2017-09-30 | $146.20M 10-Q · filed 2017-10-31 |
| 2017-06-30 | $129.57M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $129.89M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $136.09M 10-K · filed 2018-02-26 |
| 2016-09-30 | $110.87M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $100.46M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $88.67M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $75.28M 10-K · filed 2017-02-27 |
| 2015-09-30 | $82.59M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $70.78M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $76.95M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $62.57M 10-K · filed 2016-02-29 |
| 2014-09-30 | $64.02M 10-Q · filed 2014-10-28 |
| 2014-06-30 | $50.65M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $56.74M 10-Q · filed 2014-05-02 |
| 2013-12-31 | $58.88M 10-K · filed 2015-03-02 |
| 2013-09-30 | $52.34M 10-Q · filed 2013-10-28 |
| 2012-12-31 | $45.31M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |